Cargando…

Hypertensive crisis and pulmonary edema following rituximab-induced anaphylaxis

Rituximab is a monoclonal antibody against the protein CD20. Various lymphomas as well as non-malignant immune disorders are treated with this antibody. Hypersensitivity reactions associated with the use of rituximab include urticaria, hypotension, chest tightness, vomiting, oxygen desaturation and...

Descripción completa

Detalles Bibliográficos
Autores principales: Brili, Styliani, Bei, Evangelia, Kounis, Nicholas G., Chrysohoou, Christina, Antoniou, Christos-Konstantinos, Kontopidou, Flora, Bonfanti, Laura, Cervellin, Gianfranco, Tousoulis, Dimitrios, Tsioufis, Constantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523046/
https://www.ncbi.nlm.nih.gov/pubmed/34747381
http://dx.doi.org/10.23750/abm.v92iS1.11120
Descripción
Sumario:Rituximab is a monoclonal antibody against the protein CD20. Various lymphomas as well as non-malignant immune disorders are treated with this antibody. Hypersensitivity reactions associated with the use of rituximab include urticaria, hypotension, chest tightness, vomiting, oxygen desaturation and bronchospasm. A very uncommon case of hypertensive crisis and pulmonary edema following rituximab-induced hypersensitivity reaction in an 80-year-old man receiving rituximab for non-Hodgkin lymphoma is reported. Anaphylaxis manifesting as coronary vasospasm following drug treatment, including rituximab, could be proved a serious condition in patients who need specific treatment. In these patients desensitization protocols seem to be mandatory. (www.actabiomedica.it)